跳至主要内容
临床试验/NCT05978141
NCT05978141招募中不适用

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

Memorial Sloan Kettering Cancer Center50 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2023年7月27日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
50
主要终点
Number of participants populating the T-cell Lymphoma Master Repository/TCLMR

研究概览

简要总结

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
  • Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):
  • T-cell prolymphocytic leukemia
  • T-cell large granular lymphocytic leukemia
  • Chronic lymphoproliferative disorder of NK cells
  • Aggressive NK-cell leukemia
  • Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
  • Chronic active EBV infection of T- and NK-cell type, systemic form
  • Hydroa vacciniforme-like lymphoproliferative disorder
  • Adult T-cell leukemia/lymphoma
  • Extranodal NK/T-cell lymphoma, nasal type
  • Enteropathy-associated T-cell lymphoma
  • Monomorphic epitheliotropic intestinal T-cell lymphoma
  • Intestinal T-cell lymphoma, not otherwise specified (NOS)
  • Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
  • Hepatosplenic T-cell lymphoma
  • Subcutaneous panniculitis-like T-cell lymphoma
  • Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
  • Sézary syndrome
  • Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
  • Primary cutaneous Gamma-Delta T-cell lymphoma
  • Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
  • Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
  • Peripheral T-cell lymphoma, not otherwise specified
  • Angioimmunoblastic T-cell lymphoma
  • Follicular T-cell lymphoma
  • Nodal peripheral T-cell lymphoma with TFH phenotype
  • Anaplastic large cell lymphoma, ALK-positive
  • Anaplastic large cell lymphoma, ALK-negative
  • Breast-implant associated anaplastic large cell lymphoma.
  • NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

排除标准

  • Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
  • Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.

研究组 & 干预措施

Participants with T-Cell Lymphoma

Participants with pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma

干预措施: Optional Blood Sample and Nail Sample (Other)

结局指标

主要结局

Number of participants populating the T-cell Lymphoma Master Repository/TCLMR

时间窗: 10 years

To develop and populate a secure database comprised of patients with T-cell lymphomas with curated clinical characteristics and treatment outcomes matched to pathological biospecimens.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (50)

Loading locations...

相似试验